Skip to main content
Premium Trial:

Request an Annual Quote

Affy, Gen-Probe, AmeriPath Invest $7.5M in TGen s Molecular Profiling

NEW YORK, Oct. 28 (GenomeWeb News) - The Molecular Profiling Institute, the commercial arm of the Translational Genomic Institute, secured $7.5 million in capital from AmeriPath, Affymetrix, and Gen-Probe, TGen said today.

 

The funding, obtained through Series B round, will pay for additional molecular tests in breast and prostate cancers. The company will also develop assays through clinical trials targeting patients who best respond to targeted cancer therapies.

 

Molecular Profiling is a reference laboratory specializing in commercial applications of TGen's research projects and International Genomics Consortium's tissue banking and analysis capabilities. The company has an exclusive license to provide MammaPrintR 70 gene breast cancer prognostic in the United States.

 

AmeriPath currently provides Molecular Profiling's advanced tests to patients. Gen-Probe will also collaborate with Molecular Profiling to validate and commercialize its investigational PCA3 test for diagnosing prostate cancer.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.